Nanobiotix S.A.
Nanobiotix S.A. (NBTX): 1 pipeline candidate · ~2 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.7 months
D/E -1.80 · 0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for Nanobiotix S.A.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$810K
Quarterly Burn
$33.4M
Runway
1.7 mo
Revenue
$32.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| nbtxr3 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$175.8M
| Holder | Shares | Value |
|---|---|---|
| johnson & johnson | 5,623,816 | $173.6M |
| morgan stanley | 36,274 | $1.1M |
| optiver holding b.v. | 13,501 | $417K |
| marshall wace, llp | 9,239 | $285K |
| bnp paribas financial markets | 3,559 | $110K |
| rhumbline advisers | 2,281 | $70K |
| eversource wealth advisors, llc | 1,396 | $62K |
| royal bank of canada | 1,825 | $56K |
| gamma investing llc | 828 | $26K |
| osaic holdings, inc. | 500 | $15K |
Showing top 10 of 14 institutional holders of Nanobiotix S.A.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Nanobiotix S.A.'s pipeline?
Nanobiotix S.A. (NBTX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nanobiotix S.A.'s lead drug candidate?
Nanobiotix S.A.'s most advanced tracked candidate is nbtxr3 (Phase 1) for Radiotherapy.
What is Nanobiotix S.A.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nanobiotix S.A. has approximately 1.7 months of cash runway.
What is Nanobiotix S.A.'s market capitalization?
Nanobiotix S.A.'s market capitalization is approximately $1.8B.
Who is the CEO of Nanobiotix S.A.?
Dr. Laurent Levy Ph.D. is the chief executive officer of Nanobiotix S.A. (NBTX).
Get the full picture on Nanobiotix S.A.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.